LIQUIDIA CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
LIQUIDIA CORPORATION (LQDA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $583.14 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $583.14M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $269.02M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $248.39M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $152.81M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $583.14M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $269.02M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $248.39M 10-K · filed 2026-03-05 |
| 2025-09-30 | $152.81M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $68.17M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $88.51M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $62.02M 8-K · filed 2025-05-08 |
| 2024-09-30 | $46.66M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $65.68M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $90.62M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $65.56M 10-K · filed 2024-03-13 |
| 2023-09-30 | $16.77M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $29.95M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $21.84M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $16.85M 10-K · filed 2023-03-20 |
| 2022-09-30 | $10.39M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $5.13M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $18.58K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $8.75M 10-K · filed 2022-03-17 |
| 2021-09-30 | $291.10K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $220.58K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $98.08K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $38.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |